Joshua Stern, MD
Internal Medicine · New Hyde Park, NYNPI 1922087188
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $99,492 of the $125,872 with a category attached, or 79.0%. 21 manufacturers reported payments, led by Abbott at 54.5% of the total. Reporting peaked in 2022 at $38,199 and has fallen 62.6% since, to $14,292 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $218.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$69K
- Kestra Medical Technology Services, Inc.$31K
- Biotronik Inc.$20K
- Biosense Webster, Inc.$2K
- Medtronic$1K
- Impulse Dynamics (USA) Inc.$1K
- plus $2K from 15 others
What the payments were for
- Consulting fees$99,49279%
- Speaking & faculty fees$5,4504%
- Travel & lodging$7941%
- Food & beverage$19,53916%
- Education$5970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 256 | $68,654 |
| Kestra Medical Technology Services, Inc. | 49 | $30,887 |
| Biotronik Inc. | 110 | $20,063 |
| Biosense Webster, Inc. | 55 | $1,823 |
| Medtronic(2 entities) | 27 | $1,337 |
| Impulse Dynamics (USA) Inc. | 2 | $1,276 |
| Boston Scientific | 16 | $538 |
| Cumberland Pharmaceuticals, Inc. | 14 | $249 |
| Johnson & Johnson | 15 | $240 |
| Merck | 11 | $227 |
| Atricure, Inc. | 1 | $176 |
| E.r. Squibb & Sons, L.L.C. | 6 | $107 |
| Chiesi USA, Inc. | 4 | $79 |
| Vital Connect, Inc | 1 | $53 |
| Pfizer | 2 | $32 |
| Eagle Pharmaceuticals, Inc. | 1 | $25 |
| Dornier Medtech America, Inc | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$30,238
- ACCENT$17,975
- Fortify Assura, Ellipse ICD$10,939
- ACCULINK$6,375
- ALLURE$5,313
- Endurity Pacemaker$5,216
- Accent Pacemaker$4,250
- Allure Quadra RF CRT Pacemaker$4,238
- GALLANT$4,066
- Assurity Pacemaker$2,125
- Iperia$2,000
- QUADRA ASSURA$1,757
- BioMonitor$1,221
- OPTIMIZER SMART SYSTEM$1,200
- Rivacor 7 DR-T$753
- Solia$598
- Rivacor$598
- Acticor$598
- Edora$598
- JOT DX$594
How this compares
$125,872 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 545 | $632,755 |
| XareltoRivaroxaban | 153 | $180,969 |
| MultaqDronedarone Hcl | 91 | $121,787 |
| Metoprolol Succinate | 420 | $7,939 |
| Mexiletine Hcl | 34 | $3,762 |
| Amiodarone Hcl | 125 | $2,774 |
| SotalolSotalol Hcl | 56 | $1,338 |
| Pantoprazole Sodium | 95 | $708 |
| Diltiazem 24hr Er (Xr)Diltiazem Hcl | 12 | $427 |
| Carvedilol | 42 | $376 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $376 |
| ClopidogrelClopidogrel Bisulfate | 23 | $334 |
| Omeprazole | 14 | $142 |
| Metoprolol Tartrate | 13 | $109 |
| Atenolol | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $632,755545 claims |
| Johnson & JohnsonXarelto | $240 | $180,969153 claims |
| Sanofi-aventis U.S. LLCMultaq | $21 | $121,78791 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Hyde Park
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.